TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05133817
Drug: Norepinephrine (0.075 μg/kg/min)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
Study: NCT05133817
Drug: Norepinephrine (0.1 μg/kg/min)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
Study: NCT04990557
Drug: PD-1 and ACE2 Knockout T Cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
Study: NCT05098886
Drug: DA-5210 10/1000mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT05098886
Drug: DA-5210-R 10/1000mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT05998421
Drug: routine aspirin and heparin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients accepted routine aspirin and heparin treatment. Two months before pregnancy, 50 mg of aspirin (Chenxin Pharmaceutical, China) was taken orally once a day.
Study: NCT06064331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bolus of 10 ml normal saline over 3 min followed by infusion of equal volume of normal saline in 20 ml syringe
Study: NCT05369884
Drug: WPQW granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: WPQW granule, 2 sachets / time, 3 times / day.
Study: NCT05369884
Drug: WPQW granule simulant
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: WPQW granule simulant, 2 sachets / time, 3 times / day.
Study: NCT05948683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose
Study: NCT06471556
Drug: IV Methylprednisolone pulses
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six (6) pulses (max) are performed at a 4 weeks interval (+/- 10 days). Each pulse is a 3-days-6h-perfusions of Methylprednisolone (500mg and 120mg) 10mg/kg/day diluted in 50ml of saline under supervision of SpO2, heart rate, blood pressure /
Study: NCT04966546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple syrup with peppermint oil added to match the commercial solution and make it indistinguishable
Study: NCT06419166
Drug: GC012F injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) once by intravenous infusion on Day 0.~Other Name: CD19-BCMA CAR-T cells
Study: NCT05505162
Drug: EE/LNG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive two tablets of EE and LNG once on Day 1 and Day 15 as a combined oral dose.
Study: NCT06427200
Drug: oral Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral iron once daily during or after meals as add-on therapy for 12 weeks.
Study: NCT06427200
Drug: lactoferrin and oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactoferrin twice daily before meals and oral iron once daily during or after meals as add-on therapy for 12 weeks.
Study: NCT05001022
Drug: ALG-020572
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple doses of ALG-020572
Study: NCT05001022
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple doses of Placebo
Study: NCT05316428
Drug: TPN171H tablet plus alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg TPN171H tablet QD plus 0.5 g/kg alcohol
Study: NCT05316428
Drug: TPN171H tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg TPN171H tablet QD
Study: NCT05115123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06649942
Drug: KP-001
Normalized name: Draxxin KP
Approvals — FDA: no, EMA: no, PMDA: no
Description: KP-001 100 mg + placebo
Study: NCT06649942
Drug: KP-001
Normalized name: Draxxin KP
Approvals — FDA: no, EMA: no, PMDA: no
Description: KP-001 400 mg
Study: NCT06649942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06650514
Drug: OMO-103
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMO-103 administered at the recommended phase 2 dose (6.5 mg/kg as a weekly intravenous infusion in 28-day cycles).
Study: NCT05013385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05345964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take Placebo orally(once daily) on Day 1
Study: NCT05345964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take Placebo orally (once daily) from day 1 to day 7
Study: NCT04916431
Drug: mRNA-6231
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile frozen liquid dispersion for injection
Study: NCT04707157
Drug: LY3556050
Approvals — FDA: no, EMA: no, PMDA: no
Description: given orally
Study: NCT04707157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: given orally
Study: NCT05590260
Drug: IV iron infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-dose IV iron infusion
Study: NCT05590260
Drug: Oral iron tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of elemental iron
Study: NCT05332002
Drug: Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a Single Arm Phase II trial of q4week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor 2 (HER2) negative gastric and esophageal cancers (GEC).~The study treatment is a chemotherapy combination of either FOLFOX or FOLFIRI as below:~1. mFOLFOX6: (Oxaliplatin 85 mg/m2 IV, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, then 5-FU 2400 mg/m2:~2. FOLFIRI: (Irinotecan 180 mg/m2 IV, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, then 5-FU 2400 mg/m2~3. Nivolumab(Optional) The chemotherapy combination of FOLFOX and FOLFIRI is a FDA approved treatment for advanced bowel and gastric
Study: NCT06033742
Drug: HS-10374-matched placebo tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple dosing of HS-10374-matched placebo orally in a fasting state
Study: NCT05030363
Drug: ALDH enzyme supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALDH enzyme (PICOZYMEQ™)
Study: NCT06343948
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration for a cycle of 3 weeks.
Study: NCT06553664
Drug: Treat with Vibrabot capsules for at least 7 weeks
Normalized name: omega-3 acid ethyl esters (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the trial group took Vibrabot capsules at least 7 weeks, doses ranging from 2 to 5 capsules orally per week.
Study: NCT04501770
Drug: Cohort 8 of M802
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 8, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 225 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
Study: NCT05344170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a 2 mL oral dose of placebo. Placebo contains the same excipient, medium chain triglycerides (MCT) oil, as the investigational products but does not contain cannabinoids.
Study: NCT06264882
Drug: Transdermal Estradiol Patch
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment will be a weekly transdermal patch (0.075 mg) administered in a double-blinded manner. This estradiol dose increases serum estradiol to \~90 pg/mL. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.
Study: NCT06264882
Drug: Transdermal Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be a weekly transdermal patch (placebo inactive) administered in a double-blinded manner. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.
Study: NCT05648994
Drug: Cyclophosphamide Capsules
Normalized name: Cyclophosphamide Capsules
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of the non-myeloablative lymphocyte-depleting preparative regime
Study: NCT05844150
Drug: PM8002
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06402708
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: paclitaxel 60mg/m2, ivgtt; cisplatin 30mg/m2, ivgtt; 5-FU 500mg/m2, ivgtt and 500mg/m2, civ 24h; calcium folinate 200mg; q3w.
Study: NCT04169360
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: White, oblong 300 mg tablet
Study: NCT05678036
Drug: Opioid maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: A reform dramatically expanding access to opioid maintenance treatment (with methadone or buprenorphine) in the region.
Study: NCT06496815
Drug: PD-1,PD-L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/PD-L1 will be used as previous (if have).
Study: NCT05489731
Drug: VIC-1911
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIC-1911 tablets for oral administration
Study: NCT05412056
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: as in arm/group description
Study: NCT05402553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive, in addition to standard therapy, normal saline IV bolus BID for 3 days
Study: NCT05061836
Drug: 1.25%Dextrose equivalence
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5%dextrose in normal saline (5%DNSS) infused ¼ of maintenance rate
Study: NCT05061836
Drug: 2.5%Dextrose equivalence
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5%dextrose in normal saline (5%DNSS) infused ½ of maintenance rate
Study: NCT05061836
Drug: Dextrose 5
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5%dextrose in normal saline (5%DNSS) infused with maintenance rate
Study: NCT06649266
Drug: RBD1016
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBD1016, active drug.
Study: NCT06649266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo that is identical in appearance and volume to the doses of active IMP.
Study: NCT05100628
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be given at 75 mg/m\^2 as an intravenous infusion on Day 2 of the 21-day cycle for up to 6 cycles.
Study: NCT05447494
Drug: High-dose CAN103
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations.
Study: NCT05886660
Drug: Placebo Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will self-administer Placebo Nasal Gel.
Study: NCT05886660
Drug: Placebo Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will self-administer Placebo Nasal Gel.~Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject.
Study: NCT05660720
Drug: Placebo (orelabrutinib tablet simulator)
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as 8 tablets (400mg).
Study: NCT06118684
Drug: EP395 (Part A and B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP395 (test product) oral capsule 125 mg. Part A: Dose: 1 capsule as a single dose on Day 1 and Day 14, total daily dose: 125 mg.~Part B: Dose: 3 capsules once daily on Days 9 to 28, total daily dose: 375 mg.
Study: NCT04788654
Drug: Celebrex, acetaminophen, and dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological intervention will be performed. Celebrex 200mg, acetaminophen 1g, and dexamethasone 7 mg will be infused perioperatively.
Study: NCT05917561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once a month, infusion for 36 weeks
Study: NCT06486623
Drug: Black chokeberry extract in capsules with 18% standardization of the anthocyanins content
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement group: supplement of diet - black chokeberry extract (capsules) with 18% standardization of the anthocyanins content (one capsule contained 200 mg). Each capsule also contained: chokeberry fiber, E460b magnesium salts of stearic acid (anti-caking agent), E551 silicon dioxide (anti-caking agent), hydrocypropyl methylcellulose (capsule shell) and E171 titanium dioxide (shell colour).~The producer of all capsules is MLD Biotrade in Poznan.
Study: NCT05831449
Drug: Naropin, 0.5% Injectable Solution
Normalized name: Naropin, 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
Study: NCT05831449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
Study: NCT05115838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo implantable rod placed subdermally on the upper arm.
Study: NCT05308979
Drug: OnabotulinumtoxinA 100 UNT [Botox]
Normalized name: onabotulinumtoxinA 100 UNT [Botox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradetrusor (Bladder) Botox Injection at 1 vs 10 injection sites
Study: NCT05093933
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg matching placebo for 2.5 mg, 5 mg, and 10 mg of vericiguat
Study: NCT05937178
Drug: ETV/TAF/TDF/TMF/IFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alpha or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
Study: NCT06290375
Drug: HSK21542 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: once-daily
Study: NCT06290375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once-daily
Study: NCT06561009
Drug: Anti-BAFFR CART
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-BAFFR CART
Study: NCT04643067
Drug: KPG-818 mid dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
Study: NCT04643067
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the comparative arm.
Study: NCT05084911
Drug: Pyramax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyronaridine-Artesunate(180/60mg) tablet for 3days.
Study: NCT05084911
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet for 3days.
Study: NCT06331299
Drug: UGN-103
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGN-103 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-103 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
Study: NCT04936178
Drug: NB003 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: NB003 tablets will be administered at assigned doses for escalation phase and RP2D doses for expansion phase orally twice daily for repeated 28-day cycles until discontinuation criteria are met.
Study: NCT04350177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration gelatin capsule
Study: NCT05234606
Drug: SBT6290
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose expansion with the recommended Phase 2 dose (RP2D) by SC injection in 21-day cycles
Study: NCT06219577
Drug: Systane Complete Multi-Dose PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eyedrop
Study: NCT06219577
Drug: Walgreen's Lubricant Balance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eyedrop
Study: NCT04430569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
Study: NCT06228963
Drug: Triple therapy for eradication of Helicobacter Pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy for H. pylori (oral administration for 2 weeks, followed by a 1-week break)
Study: NCT06176534
Drug: Experimental: chemotheyapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel 130mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2, followed by nab-paclitaxel 130mg/m2，day 1 and day 8 or Capecitabine from day1 to DAY 14 Vinorelbine 25mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2，from day1 to DAY 14
Study: NCT06176534
Drug: Active Comparator: endocrine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: palbociclib 125mg per day for 21days Dalpiciclib 150mg per day for 21days Letrozole 2.5mg per day Anastrozole 1mg per day fulvestrant 500mg per 28 days
Study: NCT04800562
Drug: PCS499
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCS499 900mg twice a day with food
Study: NCT04860635
Drug: F14 (sustained release celecoxib)
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib in BEPO® drug delivery system
Study: NCT05633745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Doses
Study: NCT05268289
Drug: Placebo + standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken for 52 Weeks
Study: NCT06372457
Drug: Approved Hypertrophic Cardiomyopathy drug treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product label
Study: NCT05171257
Drug: IV antibiotic treatment from prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receiving same IV antibiotic treatment from prior
Study: NCT05171257
Drug: differing IV antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receiving differing IV antibiotics from prior
Study: NCT04916418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTP block with initial dose of placebo (NaCl0.9%) 20 ml per catheter (total volume 40ml), followed by 20 ml per catheter every 8 hours until 72 hours from the first dose has passed.
Study: NCT04268121
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide followed by surgery or chemoradiotherapy
Study: NCT05728541
Drug: SYH2043
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive SYH2043 once everyday on day 1-21 of each 28-day cycle
Study: NCT05060822
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo，once daily
Study: NCT06241833
Drug: PPI
Normalized name: PPIase
Approvals — FDA: no, EMA: no, PMDA: no
Description: use of PPI concomitant with DAPT
Study: NCT04808531
Drug: NanaBis™
Approvals — FDA: no, EMA: no, PMDA: no
Description: NanaBis™ is a nanoparticle water soluble equimolar solution of d9-THC \& CBD. One dose is equivalent to 2 actuations of the pump delivering 280 µL volume containing 2.5 mg d9-THC and 2.5 mg CBD
Study: NCT04808531
Drug: Placebo Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
Study: NCT04808531
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
Study: NCT05433506
Drug: HU6 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six subjects will receive a tablet formulation.
Study: NCT05433506
Drug: HU6 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six subjects will receive the capsule formulation
Study: NCT05654922
Drug: ARINA-1
Normalized name: ZOSTERA MARINA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)
Study: NCT04924868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: composition per 100g: colloidal silica 1.95g and cellulose microcrystalline 98.05g.
Study: NCT05755282
Drug: Post-market foam alcohol-based hand sanitizer #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated dispenser will dispense 1 mL of hand sanitizer product onto hands.
Study: NCT06284122
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 Day 1 from C1 to C6
Study: NCT06284122
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 Day 1 from C1 to C6
Study: NCT05121974
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Azithromycin antibiotic (Macrolides)
Study: NCT06393387
Drug: DTG/3TC versus BIC/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: A new-user, active comparator, retrospective cohort study design will be employed using inverse probability of treatment weighting to adjust for measured confounders. This study will be conducted as a retrospective chart review and the organization's electronic health record (EHR) will be utilized. Subjects identified as having previously been or currently receiving DTG/3TC or BIC/F/TAF will be assessed for eligibility based on inclusion/exclusion criteria. Subject eligibility will be confirmed by the Principal Investigator (PI).
Study: NCT04817111
Drug: MIB-626
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two (2) 500 mg Tablets, By Mouth, Daily